Peter Marks

Mr Marks has over 35 years' experience in corporate advisory and investment banking. Over the course of his career, he has specialised in capital raisings, IPOs, cross border, M&A transactions, corporate underwriting and venture capital transactions for companies in Australia, the United States and Israel. He has been involved in a range of transactions with a ]focus in the life sciences, biotechnology, medical technology and high tech segments. Peter has served as both an Executive and Non Executive Director of entities which have been listed on the ASX, NASDAQ, and AIM markets. Other current directorships are Alterity Therapeutics Limited (appointed 29 July 2005), Noxopharm Limited (appointed 15 March 2016), EverGreen Lithium Limited (appointed 21 January 2022). Former directorships (last 3 years) include Nyrada Inc (Appointed 16 January 2020, resigned 1 August 2022), Elsight Limited (appointed 9 January 2020, resigned 1 October 2021).